Amicus Therapeutics, Inc. (FOLD) stock saw a modest uptick, ending the day at $9.41 which represents a slight increase of $0.05 or 0.53% from the prior close of $9.36. The stock opened at $9.46 and ...

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” ...

Cantor Fitzgerald reiterated their overweight rating on shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) in a report released on Wednesday morning,Benzinga reports. They currently have a $21.

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on FOLD stock, giving a Buy rating on January 13.Stay Ahead of ...

Analyst Jeffrey Hung from Morgan Stanley maintained a Hold rating on Amicus (FOLD – Research Report) and keeping the price target at ...

Amicus Therapeutics grew its revenue by 33% over the last year. We think that is pretty nice growth. Unfortunately that wasn't good enough to stop the share price dropping 32%. This implies the market ...

Amicus Therapeutics reports 2024 revenue of $528M, a 32% increase, with positive 2025 growth projections for key therapies. 2024 total revenue reached $528.5 million, marking a significant year ...

Check the time stamp on this data. Updated AI-Generated Signals for Amicus Therapeutics Inc. (FOLD) available here: FOLD.